CASE REPORT article
Front. Oncol.
Sec. Breast Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1635515
Male Accessory Breast Carcinoma: A Rare Case Report and Literature Review
Provisionally accepted- The Thirteenth People's Hospital of Chongqing, Chongqing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Accessory breast carcinoma, arising from embryologically persistent mammary tissue, is exceptionally rare in males, accounting for 2.4%-5.3% of all accessory breast malignancies. Due to limited clinical data, standardized diagnostic and therapeutic protocols remain undefined.Case Presentation: A 72-year-old male presented with a 3-year history of a painless, mobile right axillary mass. Ultrasonography revealed a solid hypoechoic nodule with moderate vascularity.Histopathological examination confirmed invasive ductal carcinoma (grade II) with infiltrative growth, ER/PR/AR positivity (90%), and TRPS1 expression, confirming mammary origin. Adjuvant therapies were declined by the patient.Discussion: Differential diagnoses for axillary masses include fibroadenoma, lymphadenopathy, and cutaneous adnexal tumors. Immunohistochemistry (TRPS1, GATA-3) and histomorphology (absence of apocrine differentiation) are pivotal for distinguishing accessory breast carcinoma from mimics. Current management aligns with male breast cancer guidelines, emphasizing surgical resection, lymph node dissection, and adjuvant therapies tailored to molecular profiles. Over 90% of male breast cancers are hormone receptor-positive, warranting endocrine therapy.Male accessory breast carcinoma poses significant diagnostic challenges due to its rarity and nonspecific presentation. Clinicians should consider this entity in differential diagnoses of axillary or inguinal masses, irrespective of patient sex. Core needle biopsy and advanced imaging aid preoperative evaluation. Multimodal treatment, including surgery and risk-stratified adjuvant therapies, is critical for optimizing outcomes. This case underscores the need for heightened clinical suspicion and evidence-based guidelines to address this understudied malignancy.
Keywords: Accessory breast carcinoma, Male breast cancer, Axillary mass, TRPS1, Immunohistochemistry
Received: 26 May 2025; Accepted: 25 Aug 2025.
Copyright: © 2025 luo, W, Zhao and zeng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Song Zhao, The Thirteenth People's Hospital of Chongqing, Chongqing, China
ying zeng, The Thirteenth People's Hospital of Chongqing, Chongqing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.